To evaluate the effect of Apc001PE on bone mass and bone microarchitecture in OI mice, six-week-old Col1a2+/G610C mice (OI) were subcutaneously administrated with Apc001PE (12 mg/kg, twice per week) for six weeks. Here, COL1A2 is linked to osteogenesis imperfecta.